One variation of a system includes a cartridge comprising: a substrate; a sample well integrated into the substrate, defining an upper opening and a lower opening, and configured to receive a test solution comprising a user sample and an amount of a fluorescent probe configured to bind with a target bioparticle to form a target complex; a filter membrane extending across the lower opening and defining a network of pores configured to convey fluid from the sample well and prevent passage of the target complex through the filter membrane. The system further includes a reader comprising: a housing; a cartridge receptacle configured to receive the cartridge; an excitation source configured to illuminate a detection region within the housing; and a detector defining a field of view intersecting the detection region and configured to detect a signal generated by fluid in the sample well and representing presence of the target bioparticle.

Described herein is a method for detecting the presence of circulating extracellular vesicles in a subject. The method comprises contacting a biological sample from the subject with an antibody mimetic that specifically binds to a cell surface marker on the vesicles, wherein the antibody mimetic is coupled to a detectable label; and detecting presence of extracellular vesicles in the sample by detecting the presence of the detectable label coupled to the antibody mimetic bound to the vesicles.

The present invention discloses a freeze-dried preparation of chemiluminescent immune microspheres, and a preparation method and an application thereof. The preparation is composed of one or more spherical solid particles having the same composition, which are uniform, smooth, and highly stable. In the preparation process, a magnetic particle coating raw material, an acridinium ester marking raw material and a reagent storage agent are freeze-dried into microspheres, so that the freeze-dried preparation can be stored and transported at normal temperature; the microspheres prepared in the present invention can be sub-packaged conveniently into individual packs, which are hygienic, simple and clear, and convenient to get and use, thereby the safety and convenience of use are improved. The preparation provided by the present invention and the test kit prepared according to the present invention can be used for immunoassays that are not for a disease diagnoses or treatment purpose.

This disclosure describes methods and compositions for detecting the presence of autoantibodies associated with autoimmune polyglandualar syndrome 1 (APS1) in a biological sample. In particular, detection of APS1-specific autoantibodies that specifically bind to certain APS1 associated autoantigens in such methods is described. Also provided are methods of treating subjects with APS1 or at risk of developing APS1 associated conditions. Also provided are devices and kits useful for the diagnosis and prognostic assessment of subjects having APS1 and for assessing subject risk at developing particular APS1-associated conditions.

This disclosure describes methods and compositions for detecting the presence of autoantibodies associated with autoimmune polyglandualar syndrome 1 (APS1) in a biological sample. In particular, detection of APS1-specific autoantibodies that specifically bind to certain APS1 associated autoantigens in such methods is described. Also provided are methods of treating subjects with APS1 or at risk of developing APS1 associated conditions. Also provided are devices and kits useful for the diagnosis and prognostic assessment of subjects having APS1 and for assessing subject risk at developing particular APS1-associated conditions.

A method of detecting a particular protein contained in an extracellular vesicle, the method including the steps of: (A) capturing the extracellular vesicle using a carrier capable of binding to an extracellular-vesicle-specific marker present on the surface of the extracellular vesicle; (B) carrying out membrane permeabilization treatment for the extracellular vesicle captured by the carrier, using a membrane permeabilization treatment agent; and (C) introducing a reagent capable of detecting the particular protein contained in the extracellular vesicle, into the membrane-permeabilized extracellular vesicle; wherein Step (B) is carried out such that the particular protein does not leak to the outside of the extracellular vesicle, and such that the reagent can be introduced into the extracellular vesicle.

A sample analysis substrate mountable and detachable to a sample analysis device and includes: a plate-shaped base substrate; and a chamber, the chamber being a space in which to cause a binding reaction, The sample analysis device includes: a motor to rotate the sample analysis substrate; a first magnet unit to attract the magnetic particles; a first actuator to move the first magnet unit to change relative positions of the first magnet unit and the sample analysis substrate; and a control circuit to control the motor, the drive circuit, and the first actuator. The first magnet unit shaped as a whole shape or a partial shape of a circle or a ring. During a B/F separation for separating reacted substance from unreacted substance, the first actuator moves the first magnet unit to a position where the magnetic particles in the chamber are attracted by the first magnet unit.

The present application relates to a quantitative kit for myxovirus resistance protein 1. Specifically, a kit comprising latex particles coated with a myxovirus resistance protein 1 antibody is disclosed. Myxovirus resistance protein 1 in human serum and plasma samples and latex particles cross-linked with a myxovirus resistance protein 1 antibody are specifically binded to form a complex, which leads to an increase in absorbance. By detecting changes in immunoturbidity, a higher sensitivity and a wider detection range are reached.

There is provided a biological substance detection chip having high detection accuracy. The present technology provides a biological substance detection chip which is composed of a plurality of pixels in which the pixel includes at least a holding surface on which a biological substance is held and a photoelectric conversion unit that is provided below the holding surface and provided on a semiconductor substrate, wherein a partition wall made of a conductor is provided between the pixels on the holding surface. In addition, the present technology provides a biological substance detection device and a biological substance detection system using the biological substance detection chip.

Method and system for detecting drug and/or drug metabolites in a liquid sample, such as a wastewater sample. According to one embodiment, the method involves providing a device that includes a graphene field effect transistor and a first aptamer coupled to the graphene field effect transistor in a first well, the first aptamer being selective for a first drug or drug metabolite. Next, a liquid sample is introduced to the first aptamer of the device. Next, a sweeping liquid gate voltage is applied to the device to obtain a resistance versus liquid gate voltage plot for the device. Next, the Dirac voltage shift, if any, in the liquid gate voltage plot for the device is used to determine the presence and/or quantity of the drug or drug metabolite. Additional aptamers selective for different drugs or drug metabolites of interest may also be included in other wells of the device.